期刊文献+

百可利对6-羟多巴胺不同注射位点帕金森病模型大鼠的治疗作用 被引量:10

Effect of baicalein on brain injury induced by 6-hydroxydopamine at different sites in rats
下载PDF
导出
摘要 目的观察百可利对6-羟多巴胺(6-OHDA)内侧前脑束(MFB)和纹状体尾壳核(CPu)两个不同注射位点帕金森病(PD)模型大鼠的治疗作用,两个注射位点模型分别记为:MFB-M,CPu-M。方法运用6-OHDA两点注射法,损毁大鼠左侧中脑多巴胺能神经元,制备PD模型。记录大鼠后肢肌电(EMG)信号频率观察肌肉震颤;测定大鼠自主活动;电化学法检测纹状体内多巴胺(DA)及其代谢产物含量;免疫组化法检测大鼠脑内酪氨酸羟化酶(TH)、OX-42表达;观察神经元超微结构变化。结果给药3周后,两个注射位点的模型组行为改变趋势一致,百可利在两个注射位点的模型动物上药效表现不同,在CPu-M组可明显提高PD大鼠自主活动数(P<0.05)。EMG信号分析显示,在MFB-M组,给予百可利,肌电频率降低55%;在CPu-M组,给予百可利,肌电频率降低60%。EMG时效研究表明,在CPu-M组,百可利药效持续420 min以上。纹状体递质水平显示,两个注射位点的模型组DA递质水平差异很大,在CPu-M组,百可利能够明显升高DA水平(P<0.05)。两个注射位点的模型组免疫组织化学结果趋势一致,在CPu-M组,百可利有更明显神经元保护作用(P<0.05),在MFB-M组,百可利抑制小胶质细胞过度激活作用更强(P<0.01)。结论不同注射位点制备的PD模型能够反映不同时期PD的病理变化,百可利可通过抑制炎性介质生成和释放、保护残存神经元、恢复神经元功能等机制改善PD不同发病时期模型动物的行为学症状。 Aim To explore the therapeutical effect and mechanism of baicalein on two 6-hydroxydopamine (6-OHDA ) induced Parkinson′s disease (PD ) rat models,which received unilateral lesions of the left medial forebrain bundle (MFB ) or caudate putamen (CPu ) made by stereotaxic injection of 6-OHDA (MFB-M,CPu-M).Methods PD rat models were&nbsp;established by microinjection of 6-OHDA into MFB or CPu.The anti-tremor effect of baicalein on PD rat models was examined.Spontaneous activity was recor-ded. Dopamine (DA ), dihydroxyphenylacetic acid (DOPAC)and homovanilic acid (HVA)in striatum were quantified by HPLC-ECD.The tyrosine hydroxy-lase (TH)and OX-42 positive cells were detected by&nbsp;immunohistochemical method.The morphological vari-ation of the neurons was confirmed by analysis at an ul-trastructural level.Results Baicalein significantly in-creased the spontaneous activity in CPu-M.The elec-tromyography (EMG ) recordings revealed that com-pared with 6-OHDA group,the tremor frequency in ba-icalein group was decreased by 55% in MFB-M,and by 60% in CPu-M.6-OHDA treatment decreased DA levels in the striatum,while treatment with baicalein attenuated the DA decreases in CPu-M.Moreover,ba-icalein treatment could increase TH-positive neurons and decrease OX-42-postive microglia compared with 6-OHDA group in both MFB-M and CPu-M.Conclu-sions In the present study,it is illustrated that ①microinjection of 6-OHDA into the MFB and the CPu could cause different pathological changes of PD, which is important for efficacy evaluation;②baicalein showed the ability to alleviate the behavior symptoms in PD-rats at different stages by improving motor function and attenuating muscle tremor;③therapeutic effect of baicalein was produced by inhibiting the inflammatory medium production and release,anti-apoptosis,chan-ging dopamine catabolism, and inhibiting dopamine turnover.
出处 《中国药理学通报》 CAS CSCD 北大核心 2015年第5期623-630,共8页 Chinese Pharmacological Bulletin
基金 国家科技部"重大新药创制"科技重大专项"(No2013ZX09102106 2013ZX09508104 2012ZX09301002001001 2013ZX09103001-008 2012ZX09103101-078) 国家自然科学基金资助项目(No 81473383)
关键词 百可利 帕金森病 6-羟多巴胺 黑质纹状体通路 内侧前脑束 纹状体尾壳核 神经保护 baicalein Parkinson′s disease 6-hydroxydopamine nigrostriatal pathway medial fore-brain bundle caudate putamen neuroprotective
  • 相关文献

参考文献4

二级参考文献44

  • 1Xiao-Guang LUO Hong WANG Jin ZHOU Rong YAN Zhe WU Chao-Dong ZHANG Qiu-Shuang WANG.Beneficial effects of BV2 cell on proliferation and neuron-differentiating of mesenchymal stem cells in the circumstance of injured PC12 cell supernatant[J].Neuroscience Bulletin,2006,22(4):221-226. 被引量:3
  • 2孙斌,罗毅.丙炔苯丙胺治疗帕金森病30例临床观察[J].卒中与神经疾病,1997,4(2):60-62. 被引量:3
  • 3Cristina S, Zangaglia R, Mancini F. High-dose ropinirole in advanced Parkinson 's disease with severe dyskinesias[J]. Clin Neuropharnuwol, 2003,26(3) :146 - 150.
  • 4Simpkins N, Jankovic J. Neuroprotection in Parkinson's disease[ J ]. Arch Intern Med, 2003, 163 (14) : 1650 -1654.
  • 5Gatto E M, Riobo N, Carreras M C, Neuroprotection in Parkinson's disease: a commentary [ J ]. Neurotoxicology,2002,4(2) :141 - 145.
  • 6Fariss M W, Zhang J G. Vitamin E therapy in Parkinson's disease[J]. Toxicology, 2003, 189 (1-2) : 129 - 146.
  • 7Sagi Y, Weinstock M, Youdim M B. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor [ J ]. J Neurochem, 2003,86 ( 2 ) : 290 - 297.
  • 8Van L T. Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management[J]. Drugs, 2003,17(7) :475 -489.
  • 9Souza S, Barnett S K, Rangu S. Treatment of psychosis in Parkinson's disease [ J ]. J Am Med Diet Assoc, 2000, 1(5) :211 -216.
  • 10Ikebe S, Harada T, Hashimoto T, et al. Prevention and treatment of malignant syndrome in Parkinson's disease: a consensus statement of the malignant syndrome researchgroup[ J]. Parkinsonism Relat Disord, 2003,9 ( Suppl 1 ) :47 - 49.

共引文献382

同被引文献95

引证文献10

二级引证文献101

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部